<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953624</url>
  </required_header>
  <id_info>
    <org_study_id>M2020399</org_study_id>
    <nct_id>NCT04953624</nct_id>
  </id_info>
  <brief_title>Appetite and Related Factors in Patients With ALS</brief_title>
  <official_title>Detection of Appetite and Analysis of Related Factors in Patients With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chinese cnaq scale was used to evaluate the appetite changes of Chinese ALS patients;&#xD;
      Objective to investigate the related factors of appetite changes in ALS patients; Objective&#xD;
      to investigate the effect of anorexia on the progression and survival of ALS patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. With the consent of the original author, the scale was translated and back translated,&#xD;
           and the Chinese version of the scale was determined after communication and confirmation&#xD;
           with the original author.&#xD;
&#xD;
        2. Cnaq was used to measure the appetite of the patients, and hads was used to measure the&#xD;
           anxiety and depression of the patients;&#xD;
&#xD;
        3. Analyze the proportion of loss of appetite in ALS group, compare the differences of&#xD;
           clinical characteristics such as ALSFRS-R score, weight, BMI value, cognitive status&#xD;
           such as ECAs score between patients with loss of appetite and patients without loss of&#xD;
           appetite in ALS group, and conduct correlation analysis.&#xD;
&#xD;
        4. The patients were followed up every three months until they were unable to eat or&#xD;
           end-point events (invasive ventilator or death), and the correlation between cnaq and&#xD;
           disease progression and survival was analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ALSFRS-R score</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ALSFRS-R score</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ALSFRS-R score</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Food intake</measure>
    <time_frame>3 months</time_frame>
    <description>Inability to eat</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Food intake</measure>
    <time_frame>6 months</time_frame>
    <description>Inability to eat</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Food intake</measure>
    <time_frame>12 months</time_frame>
    <description>Inability to eat</description>
  </primary_outcome>
  <primary_outcome>
    <measure>invasive ventilator or death</measure>
    <time_frame>3 months</time_frame>
    <description>end point events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>invasive ventilator or death</measure>
    <time_frame>6 months</time_frame>
    <description>end point events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>invasive ventilator or death</measure>
    <time_frame>12 months</time_frame>
    <description>end point events</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>CNAQ≤28</arm_group_label>
    <description>ALS patients with CNAQ ≤ 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNAQ&gt;28</arm_group_label>
    <description>ALS patients with CNAQ &gt; 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Appetite rating scale CNAQ</intervention_name>
    <description>Chinese version of Appetite rating scale CNAQ</description>
    <arm_group_label>CNAQ&gt;28</arm_group_label>
    <arm_group_label>CNAQ≤28</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ALS patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ALS patients diagnosed as probable, or definite according to the revised El Escorial&#xD;
             criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  there are other chronic consumption diseases such as severe digestive system diseases,&#xD;
             thyroid diseases, diabetes and so on.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongsheng Fan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dongsheng Fan</last_name>
    <phone>+86 13701023871</phone>
    <email>dsfan@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100098</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongsheng Fan</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

